Medline Inc. Class A Common Stock (MDLN)vsRepligen Corporation (RGEN)
MDLN
Medline Inc. Class A Common Stock
$42.67
+1.52%
HEALTHCARE · Cap: $34.68B
RGEN
Repligen Corporation
$114.32
-1.70%
HEALTHCARE · Cap: $6.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 3751% more annual revenue ($28.43B vs $738.26M). RGEN leads profitability with a 6.6% profit margin vs 4.1%. MDLN trades at a lower P/E of 29.9x. MDLN earns a higher WallStSmart Score of 52/100 (C-).
MDLN
Buy52
out of 100
Grade: C-
RGEN
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.7%
Fair Value
$66.92
Current Price
$42.67
$24.25 discount
Margin of Safety
-246.3%
Fair Value
$40.25
Current Price
$114.32
$74.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
18.1% revenue growth
Areas to Watch
Moderate valuation
ROE of 6.5% — below average capital efficiency
4.1% margin — thin
Negative free cash flow — burning cash
1.6% earnings growth
ROE of 2.4% — below average capital efficiency
6.6% margin — thin
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : MDLN
Revenue growth of 14.8% demonstrates continued momentum.
Bull Case : RGEN
The strongest argument for RGEN centers on Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.
Bear Case : RGEN
The primary concerns for RGEN are EPS Growth, Return on Equity, Profit Margin. A P/E of 135.2x leaves little room for execution misses.
Key Dynamics to Monitor
MDLN profiles as a value stock while RGEN is a growth play — different risk/reward profiles.
RGEN is growing revenue faster at 18.1% — sustainability is the question.
RGEN generates stronger free cash flow (17M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (52/100 vs 45/100) and 14.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Repligen Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?